Lusutrombopag
- Generic Name
- Lusutrombopag
- Brand Names
- Mulpleta, Mulpleo (previously Lusutrombopag Shionogi)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32Cl2N2O5S
- CAS Number
- 1110766-97-6
- Unique Ingredient Identifier
- 6LL5JFU42F
- Background
Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well, including erythroid, granul...
- Indication
Lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.
- Associated Conditions
- Chronic immune thrombocytopenia
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath